Variables | NLR <2.3 (N = 371) | p Value | 2.3 ≤ NLR ≤ 3.4 (N = 375) | p Value | NLR >3.4 (N = 380) | p Value | |||
---|---|---|---|---|---|---|---|---|---|
Sternotomy CABG | MICS | Sternotomy CABG | MICS | Sternotomy CABG | MICS | ||||
n | 242 | 129 | 245 | 130 | 243 | 137 | |||
In-hospital medication | |||||||||
Aspirin | 238 (98.3%) | 128 (99.2%) | 0.66 | 234 (95.9%) | 130 (100%) | 0.02 | 237 (97.5%) | 137 (100%) | 0.09 |
Clopidogrel | 110 (45.5%) | 111 (86.0%) | <0.001 | 128 (52.5%) | 115 (88.5%) | <0.001 | 120 (49.4%) | 116 (84.7%) | <0.001 |
Beta-blockers | 232 (95.9%) | 124 (96.1%) | 0.91 | 230 (94.3%) | 128 (98.5%) | 0.06 | 231 (95.1%) | 135 (98.5%) | 0.08 |
Angiotensin convertase inhibitor | 84 (34.7%) | 44 (34.1%) | 0.91 | 96 (39.3%) | 31 (23.8%) | 0.00 | 104 (42.8%) | 45 (32.8%) | 0.06 |
Angiotensin receptor blocker | 29 (12.0%) | 13 (10.1%) | 0.58 | 17 (7.0%) | 13 (10.0%) | 0.30 | 19 (7.8%) | 17 (12.4%) | 0.14 |
Warfarin | 18 (7.4%) | 7 (5.4%) | 0.46 | 18 (7.4%) | 8 (6.2%) | 0.66 | 26 (10.7%) | 9 (6.6%) | 0.18 |
Statin | 232 (95.9%) | 127 (98.4%) | 0.23 | 229 (93.9%) | 126 (96.9%) | 0.20 | 228 (93.8%) | 132 (96.4%) | 0.29 |
Medication on discharge | |||||||||
Aspirin | 237 (98.3%) | 125 (97.7%) | 0.70 | 234 (95.9%) | 127 (97.7%) | 0.56 | 230 (95.4%) | 131 (97.8%) | 0.26 |
Clopidogrel | 66 (27.4%) | 101 (78.9%) | <0.001 | 83 (34.0%) | 105 (80.8%) | <0.001 | 64 (26.6%) | 104 (77.6%) | <0.001 |
Beta-blockers | 212 (88.0%) | 114 (89.1%) | 0.76 | 216 (88.5%) | 117 (90.0%) | 0.66 | 208 (86.3%) | 123 (91.8%) | 0.11 |
Angiotensin convertase inhibitor | 70 (29.0%) | 32 (25.0%) | 0.41 | 67 (27.5%) | 24 (18.5%) | 0.05 | 75 (31.1%) | 27 (20.1%) | 0.02 |
Angiotensin receptor blocker | 1 (0.4%) | 4 (3.1%) | 0.05 | 4 (1.7%) | 1 (0.8%) | 0.66 | 2 (0.8%) | 7 (5.2%) | 0.01 |
Warfarin | 30 (12.4%) | 17 (13.3%) | 0.82 | 27 (11.1%) | 12 (9.2%) | 0.58 | 43 (17.8%) | 11 (8.2%) | 0.01 |
Statin | 220 (91.3%) | 119 (93.0%) | 0.57 | 222 (91.0%) | 120 (92.3%) | 0.66 | 218 (90.5%) | 123 (91.8%) | 0.67 |
Operative data | |||||||||
Internal mammary artery utilized | 231 (95.5%) | 127 (98.4%) | 0.23 | 230 (94.3%) | 128 (97.7%) | 0.13 | 221 (90.9%) | 134 (97.8%) | 0.01 |
Number of conduits used for bypass | 3.28 ± 0.991 | 2.12 ± 0.673 | <0.001 | 3.26 ± 0.886 | 2.28 ± 0.806 | <0.001 | 3.12 ± 0.910 | 2.17 ± 0.753 | <0.001 |
Cardiopulmonary bypass | 27 (11.2%) | 6 (4.7%) | 0.04 | 30 (12.3%) | 7 (5.3%) | 0.03 | 18 (7.4%) | 8 (5.8%) | 0.56 |
Postoperative complications | |||||||||
Renal Failure on Dialysis | 1 (0.4%) | 2 (1.6%) | 0.28 | 3 (1.2%) | 4 (3.1%) | 0.25 | 12 (4.9%) | 3 (2.2%) | 0.19 |
New onset atrial fibrillation | 33 (13.6%) | 22 (17.1%) | 0.38 | 40 (16.4%) | 30 (22.9%) | 0.12 | 48 (19.8%) | 43 (31.4%) | 0.01 |
Septicemia | 0 (0%) | 5 (3.9%) | 0.005 | 0 (0%) | 2 (1.5%) | 0.12 | 6 (2.5%) | 2 (1.5%) | 0.72 |